Klingberg F, Chau G, Walraven M, Boo S, Koehler A, Chow ML, et al
Pfizers dose-optimization studies of once-daily formulations of danuglipron (NCT06567327 and NCT06568731) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron
It requires covered employers to provide eligible employees with up to 12 weeks of unpaid, job-protected leave per year for qualifying reasons, including the birth or adoption of a child, a serious health condition of the employee or a close family member, or qualifying military exigencies
Du M, Yin J, Zhu MJ
Get started today with NAD or Glutathione shots at home
doi: 10.1186/1748-717X-8-72 389